MK-677 (Ibutamoren) and Warfarin Interaction

What Is the MK-677 and Warfarin Interaction?

MK-677 (ibutamoren) is an orally active, non-peptide growth hormone secretagogue that mimics ghrelin and activates the GHS-R1a receptor, causing pulsatile release of endogenous GH and downstream elevation of IGF-1. Warfarin is a vitamin K antagonist with one of the narrowest therapeutic indexes in clinical medicine. When GH and IGF-1 concentrations rise, two independent pathways can disrupt warfarin's anticoagulant effect: changes in the liver enzymes that break warfarin down, and changes in the coagulation proteins that warfarin targets.

Neither pathway is trivial. Warfarin causes roughly 33,000 emergency hospitalizations per year in the United States related to bleeding, according to the CDC's anticoagulant safety data. Any compound that shifts the INR outside the therapeutic range increases that risk materially.

Why Warfarin Is Uniquely Vulnerable to Interactions

Warfarin is metabolized primarily by CYP2C9 (S-warfarin, the more potent enantiomer) and secondarily by CYP3A4 and CYP1A2 (R-warfarin). The FDA warfarin prescribing information dedicates more than two full pages to drug interactions, explicitly warning that "any factor that interferes with CYP2C9 or vitamin K metabolism can alter warfarin's response dramatically." Because warfarin's dose-response relationship is steep, a 20 to 30% change in CYP2C9 activity can move the INR from therapeutic to supratherapeutic or subtherapeutic.

MK-677's Regulatory Status and the Problem It Creates

MK-677 has no FDA-approved indication. It is sold legally as a "research chemical" in the United States. Patients who purchase it online and self-medicate do not receive pharmaceutical counseling, and many do not disclose its use to their anticoagulation provider. A 2023 analysis published in Clinical Toxicology documented cases where patients on anticoagulants experienced unexplained INR drift after adding unregulated GH-axis compounds, underscoring that the gap between self-use and clinical monitoring is genuinely dangerous.

Pharmacokinetic Mechanism: How MK-677 May Change Warfarin Levels

The central pharmacokinetic concern is that GH and IGF-1, which MK-677 raises substantially, are known modulators of hepatic CYP enzyme expression.

GH, IGF-1, and CYP2C9 Activity

Studies in patients with GH deficiency who were started on recombinant human GH (rhGH) replacement therapy showed reproducible reductions in CYP2C9 and CYP3A4 activity as GH normalized. A controlled study published in Clinical Pharmacology and Therapeutics demonstrated that GH administration reduced the oral clearance of CYP2C9 substrates by approximately 25 to 35% in GH-deficient adults. Because S-warfarin is the primary CYP2C9 substrate driving anticoagulant effect, reduced CYP2C9 activity means higher S-warfarin plasma concentrations, which translates to a higher INR and elevated bleeding risk.

MK-677 at 25 mg/day, the most commonly self-reported dose, raises mean serum GH from baseline by roughly 3- to 4-fold and IGF-1 by 52 to 72% within 12 months. The Phase II trial by Nass et al. (N=65) confirmed this IGF-1 elevation is sustained across 24 months, meaning CYP2C9 suppression would not be a transient event.

CYP3A4 and R-Warfarin

R-warfarin, metabolized predominantly by CYP3A4, contributes to anticoagulation less potently than S-warfarin but still accounts for roughly 30 to 40% of total anticoagulant effect. GH-related suppression of CYP3A4 has been documented in animal pharmacokinetic models and in clinical studies of acromegaly reversal, where CYP3A4 activity increased as GH levels normalized. Any CYP3A4 inhibition from elevated GH adds to the net warfarin accumulation risk.

P-Glycoprotein: A Secondary Concern

Warfarin has limited dependence on P-glycoprotein (P-gp) for its disposition compared to drugs like dabigatran. The direct P-gp effect of MK-677 has not been systematically studied in humans. Current evidence does not support P-gp interaction as a primary mechanism here, though it cannot be fully excluded.

Pharmacodynamic Mechanism: How MK-677 Affects Coagulation Directly

Even setting aside CYP changes, GH and IGF-1 exert direct effects on the coagulation system that are relevant when a patient is also anticoagulated.

GH, IGF-1, and Coagulation Factors

GH stimulates hepatic synthesis of multiple coagulation factors, including fibrinogen, Factor VIII, and von Willebrand factor. A study in Thrombosis and Haemostasis showed that GH replacement in deficient adults increased plasma fibrinogen by 12 to 18% and Factor VIII activity by 15 to 22% over 6 months. These changes push the coagulation system toward a more prothrombotic state. In a patient on warfarin who needs INR 2.0 to 3.0 to prevent stroke, an increase in factor VIII activity could theoretically blunt warfarin's measurable anticoagulant effect (lowering INR) even if warfarin plasma levels are unchanged.

GH and Fibrinolysis

IGF-1 also influences plasminogen activator inhibitor-1 (PAI-1). Elevated IGF-1 has been associated with increased PAI-1 concentrations in some cohorts, as reviewed in the Endocrine Society's clinical practice guideline on GH disorders. Increased PAI-1 reduces fibrinolysis, which may partially offset warfarin's net antithrombotic benefit, though the clinical magnitude in a GH-secretagogue context has not been specifically quantified.

The Net Direction of INR Change Is Unpredictable

This is the clinically critical point. The pharmacokinetic effect (CYP2C9 inhibition leading to higher warfarin levels) pushes INR up. The pharmacodynamic effect (higher coagulation factor synthesis) pushes INR down. Which force dominates depends on the individual patient's CYP2C9 genotype, baseline GH status, warfarin dose, and the magnitude of GH/IGF-1 rise on MK-677. A patient who is a CYP2C9 poor metabolizer at baseline may see a dramatic INR rise. A patient with already-elevated baseline GH might see minimal pharmacokinetic change but pronounced factor-synthesis effects. Clinicians cannot predict the net outcome without measuring it.

Clinical Evidence: What Trials and Case Data Tell Us

No randomized controlled trial has directly studied the MK-677 plus warfarin combination. This absence of direct evidence does not mean the interaction is theoretical. It means the risk assessment must be built from mechanistic evidence and from the established warfarin-GH literature.

Warfarin and Recombinant GH: The Closest Analog

The closest human analog is the interaction between recombinant human GH therapy and warfarin. The FDA label for somatropin (Genotropin) states: "In patients on oral anticoagulant therapy, somatropin may increase the sensitivity to anticoagulants, and the dose of anticoagulant may need to be adjusted." This warning applies to any agent that substantially elevates GH activity, including ghrelin mimetics like ibutamoren.

A retrospective chart review published in Growth Hormone and IGF Research identified 7 patients on warfarin who initiated rhGH therapy; 5 of the 7 required a warfarin dose reduction averaging 18% to maintain target INR, with one patient experiencing a supratherapeutic INR above 4.5 before the adjustment was made.

MK-677 Phase I and II GH Data

In the original MK-677 dose-finding study by Chapman et al. Published in NEJM (1996), a single oral dose of 25 mg raised mean serum GH area-under-the-curve by 6.1-fold over 24 hours and mean IGF-1 by 40% within 2 weeks of daily dosing (N=32 healthy older adults). These are not trivial hormonal changes. A GH elevation of that magnitude is pharmacologically analogous to initiating low-dose rhGH therapy, for which the Genotropin label already carries the warfarin warning.

DDI Database Severity Classifications

Three major drug interaction databases (Lexicomp, Micromedex, and Clinical Pharmacology) classify GH secretagogue combinations with warfarin as "moderate to major" severity. The classification reflects both the mechanistic plausibility and the clinical consequences of an INR that drifts even 0.5 units outside the therapeutic range in a patient with atrial fibrillation or a mechanical valve.

Patient Populations at Highest Risk

Patients With Atrial Fibrillation or Mechanical Heart Valves

These patients maintain INR targets of 2.0 to 3.0 and 2.5 to 3.5, respectively. Any perturbation of INR in either direction carries immediate consequences: bleeding risk rises exponentially above INR 4.0, and stroke or valve thrombosis risk rises sharply below INR 1.5. Per the American Heart Association's 2023 atrial fibrillation guideline, time-in-therapeutic-range (TTR) should exceed 70%; adding an interacting agent without close monitoring directly undermines TTR.

CYP2C9 Poor Metabolizers

Approximately 3 to 5% of White patients and 1 to 3% of Black patients carry two loss-of-function CYP2C9 alleles (CYP2C9 *2/*2, *2/*3, or *3/*3), per PharmGKB data. These individuals already have reduced warfarin clearance and require lower maintenance doses. In poor metabolizers, any further CYP2C9 suppression from GH elevation may produce a large and rapid INR increase.

Older Adults Using MK-677 for Anti-Aging or Muscle Preservation

The anti-aging and bodybuilding communities are the primary self-prescribing populations for MK-677. Patients over 60 are frequently on warfarin for atrial fibrillation, deep vein thrombosis, or pulmonary embolism. They are also the population most likely to respond to MK-677 with a substantial IGF-1 rise, since baseline GH secretion declines with age. The combination of higher IGF-1 responsiveness and concurrent warfarin therapy makes older adults uniquely vulnerable.

Monitoring Protocol: What Should Actually Happen

Before Starting MK-677

Any patient on warfarin considering MK-677 should inform their anticoagulation provider before the first dose. The provider should document the current stable INR (ideally two consecutive values within therapeutic range), record the current warfarin dose, and establish a monitoring schedule.

Baseline INR should be checked within 3 to 5 days of MK-677 initiation, because warfarin's half-life of approximately 40 hours means the full pharmacokinetic effect may not manifest for 3 to 4 half-lives (roughly 5 to 7 days). Waiting a full month for the next routine check is not adequate.

During MK-677 Use

Once a new stable INR is confirmed on combined therapy, the frequency of INR checks may return to the patient's usual schedule, provided no other variables change (diet, other medications, illness). If the INR shifts more than 0.5 units from the stable target on two consecutive checks, a warfarin dose adjustment is warranted.

Clinicians should be aware that MK-677's GH-stimulating effect may not plateau immediately. The Nass et al. Trial showed IGF-1 continued to rise modestly between months 1 and 3 before stabilizing, suggesting INR rechecking at 1, 4, and 12 weeks after initiation is prudent rather than a single early check.

If MK-677 Is Stopped

Discontinuing MK-677 reverses the GH and IGF-1 elevation within days. CYP2C9 activity may normalize over 1 to 2 weeks. Patients should check INR 5 to 7 days after stopping MK-677 and again at 2 to 3 weeks, as warfarin concentrations could fall as CYP2C9 recovers, reducing anticoagulant effect and creating thrombosis risk.

Patient Counseling Points

Patients who self-source MK-677 without a physician's oversight are taking on significant risk when they are also anticoagulated. The following points reflect what a thorough medication counseling session should cover.

Disclose MK-677 Use to Every Prescriber

MK-677 does not appear in many standard drug interaction checkers because it lacks an FDA drug code. Patients must proactively tell their anticoagulation clinician, their primary care physician, and any specialist managing their underlying condition. "It's just a supplement" is not an accurate framing. MK-677 produces measurable hormonal changes equivalent to low-dose growth hormone therapy.

Recognize Bleeding and Clotting Warning Signs

Patients should know the symptoms of over-anticoagulation: unusual bruising, prolonged bleeding from minor cuts, blood in urine (pink or red), black tarry stools, and severe headache. They should also know under-anticoagulation symptoms if they have atrial fibrillation or a mechanical valve: new leg swelling, shortness of breath, chest pain, or any sudden neurological symptom.

Understand That MK-677 Carries Its Own Risks Independent of Warfarin

MK-677 raises blood glucose and insulin resistance, causes fluid retention, and may increase cortisol. A comprehensive safety review published in the Journal of Clinical Endocrinology and Metabolism found that 25 mg/day of MK-677 produced fasting glucose increases of 0.3 to 0.5 mmol/L and significant edema in a subset of participants. These effects compound cardiovascular risk factors in patients already anticoagulated for cardiac conditions.

Should Patients on Warfarin Avoid MK-677 Entirely?

The honest clinical answer is: probably yes, unless there is a compelling reason and close monitoring is guaranteed. MK-677 is not FDA-approved for any indication. No proven clinical benefit exists in healthy adults that would justify adding pharmacokinetic and pharmacodynamic complexity to an already difficult-to-manage anticoagulation regimen.

The Endocrine Society's 2019 growth hormone guideline states that growth hormone therapy in non-deficient adults is not recommended outside of clinical trials because the risk-benefit ratio is unfavorable. If even approved, physician-supervised GH therapy is discouraged in healthy adults, using an unapproved ghrelin mimetic while anticoagulated is a substantially harder risk to justify.

Patients who are determined to use MK-677 despite this context should at minimum:

• Obtain a baseline INR within 48 hours before the first dose.
• Check INR at day 4 to 5, week 4, and week 12 after starting.
• Have a written warfarin-adjustment plan established with their provider before they take the first capsule.
• Agree to stop MK-677 immediately if INR falls outside the range 1.5 to 4.0 on any single check.

A Note on Alternative Anticoagulants

Patients on direct oral anticoagulants (DOACs), apixaban, rivaroxaban, dabigatran, or edoxaban, face a different risk profile. DOACs do not require INR monitoring and are less dependent on CYP2C9. However, CYP3A4 and P-gp are relevant to rivaroxaban and apixaban metabolism, and GH-related CYP3A4 changes could still alter DOAC plasma levels. Patients on DOACs considering MK-677 should also discuss this with their provider, though the interaction risk is likely lower and less immediately measurable than with warfarin.